Enhanced NK activity during blast crisis in chronic myelogenous leukemia (CML) 1992

V Delwail, and A Meseri, and A Brizard, and J C Lecron, and A Sadoun, and F Costerousse, and F Guilhot, and J Tanzer, and P Goube de Laforest

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001752 Blast Crisis An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%. Blast Phase,Blast Crises,Blast Phases,Crises, Blast,Crisis, Blast,Phase, Blast,Phases, Blast
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015464 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. Granulocytic Leukemia, Chronic,Leukemia, Granulocytic, Chronic,Leukemia, Myelocytic, Chronic,Leukemia, Myelogenous, Chronic,Leukemia, Myeloid, Chronic,Myelocytic Leukemia, Chronic,Myelogenous Leukemia, Chronic,Myeloid Leukemia, Chronic,Leukemia, Chronic Myelogenous,Leukemia, Chronic Myeloid,Leukemia, Myelogenous, Ph1 Positive,Leukemia, Myelogenous, Ph1-Positive,Leukemia, Myeloid, Ph1 Positive,Leukemia, Myeloid, Ph1-Positive,Leukemia, Myeloid, Philadelphia Positive,Leukemia, Myeloid, Philadelphia-Positive,Myelogenous Leukemia, Ph1-Positive,Myeloid Leukemia, Ph1-Positive,Myeloid Leukemia, Philadelphia-Positive,Chronic Granulocytic Leukemia,Chronic Granulocytic Leukemias,Chronic Myelocytic Leukemia,Chronic Myelocytic Leukemias,Chronic Myelogenous Leukemia,Chronic Myelogenous Leukemias,Chronic Myeloid Leukemia,Chronic Myeloid Leukemias,Granulocytic Leukemias, Chronic,Leukemia, Chronic Granulocytic,Leukemia, Chronic Myelocytic,Leukemia, Ph1-Positive Myelogenous,Leukemia, Ph1-Positive Myeloid,Leukemia, Philadelphia-Positive Myeloid,Leukemias, Chronic Granulocytic,Leukemias, Chronic Myelocytic,Leukemias, Chronic Myelogenous,Leukemias, Chronic Myeloid,Leukemias, Ph1-Positive Myelogenous,Leukemias, Ph1-Positive Myeloid,Leukemias, Philadelphia-Positive Myeloid,Myelocytic Leukemias, Chronic,Myelogenous Leukemia, Ph1 Positive,Myelogenous Leukemias, Chronic,Myelogenous Leukemias, Ph1-Positive,Myeloid Leukemia, Ph1 Positive,Myeloid Leukemia, Philadelphia Positive,Myeloid Leukemias, Chronic,Myeloid Leukemias, Ph1-Positive,Myeloid Leukemias, Philadelphia-Positive,Ph1-Positive Myelogenous Leukemia,Ph1-Positive Myelogenous Leukemias,Ph1-Positive Myeloid Leukemia,Ph1-Positive Myeloid Leukemias,Philadelphia-Positive Myeloid Leukemia,Philadelphia-Positive Myeloid Leukemias

Related Publications

V Delwail, and A Meseri, and A Brizard, and J C Lecron, and A Sadoun, and F Costerousse, and F Guilhot, and J Tanzer, and P Goube de Laforest
November 1985, Blut,
V Delwail, and A Meseri, and A Brizard, and J C Lecron, and A Sadoun, and F Costerousse, and F Guilhot, and J Tanzer, and P Goube de Laforest
June 1973, [Rinsho ketsueki] The Japanese journal of clinical hematology,
V Delwail, and A Meseri, and A Brizard, and J C Lecron, and A Sadoun, and F Costerousse, and F Guilhot, and J Tanzer, and P Goube de Laforest
February 1984, American journal of hematology,
V Delwail, and A Meseri, and A Brizard, and J C Lecron, and A Sadoun, and F Costerousse, and F Guilhot, and J Tanzer, and P Goube de Laforest
May 1978, Southern medical journal,
V Delwail, and A Meseri, and A Brizard, and J C Lecron, and A Sadoun, and F Costerousse, and F Guilhot, and J Tanzer, and P Goube de Laforest
September 1993, American journal of hematology,
V Delwail, and A Meseri, and A Brizard, and J C Lecron, and A Sadoun, and F Costerousse, and F Guilhot, and J Tanzer, and P Goube de Laforest
March 1981, JAMA,
V Delwail, and A Meseri, and A Brizard, and J C Lecron, and A Sadoun, and F Costerousse, and F Guilhot, and J Tanzer, and P Goube de Laforest
September 1983, Blood,
V Delwail, and A Meseri, and A Brizard, and J C Lecron, and A Sadoun, and F Costerousse, and F Guilhot, and J Tanzer, and P Goube de Laforest
January 1984, Deutsche medizinische Wochenschrift (1946),
V Delwail, and A Meseri, and A Brizard, and J C Lecron, and A Sadoun, and F Costerousse, and F Guilhot, and J Tanzer, and P Goube de Laforest
November 2012, Blood,
V Delwail, and A Meseri, and A Brizard, and J C Lecron, and A Sadoun, and F Costerousse, and F Guilhot, and J Tanzer, and P Goube de Laforest
January 2007, Acta haematologica,
Copied contents to your clipboard!